BERLIN, Germany, Dec. 19, 2008 (GLOBE NEWSWIRE) -- Epigenomics AG (Other OTC:EPGNF.PK - News) (Frankfurt:ECX.F - News) (ISIN:DE000A0BVT96) and Royal Philips Electronics (NYSE:PHG - News) (AEX:PHI) today entered into a collaboration and licensing agreement focusing on novel technologies and methods targeted at the diagnosis of various cancers. Under the agreement both parties will jointly perform feasibility studies aimed at developing an integrated and fully automated instrument platform for the diagnosis of certain cancers based on DNA methylation biomarkers. In addition, Philips obtained the option to license the required technologies and biomarkers separately or in combination for diagnostic applications. The option may be exercised upon the successful completion of the feasibility studies. Financial details are not disclosed.
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
Contact:
Epigenomics AG Dr. Achim Plum, Sen. VP Corporate Development +49 30 24345 368 Fax: +49 30 24345 555 achim.plum@epigenomics.com www.epigenomics.com
Source: Epigenomics AG
